These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 29327946

  • 1. Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.
    Liu H, Song X, Hou J, Zhao Z, Chang J.
    DNA Cell Biol; 2018 Mar; 37(3):210-219. PubMed ID: 29327946
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, Cui Z, Zheng Z, Wang E, Wei M.
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
    Ma L, Liu T, Jin Y, Wei J, Yang Y, Zhang H.
    Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
    [Abstract] [Full Text] [Related]

  • 7. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.
    Lin F, Wen D, Wang X, Mahato RI.
    Biomaterials; 2019 Feb; 192():95-108. PubMed ID: 30447399
    [Abstract] [Full Text] [Related]

  • 8. Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer.
    Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, Meng D, Du W, Huang Y, Wu H, Wang J, Li T, Li Y.
    Clin Cancer Res; 2014 May 01; 20(9):2312-25. PubMed ID: 24610824
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.
    Wang Z, Ravula R, Shi L, Song Y, Yeung S, Liu M, Lau B, Hao J, Wang J, Lam CW, Chow MS, Huang Y.
    Oncotarget; 2016 Sep 20; 7(38):61246-61261. PubMed ID: 27487134
    [Abstract] [Full Text] [Related]

  • 11. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
    Zhang G, Tian X, Li Y, Wang Z, Li X, Zhu C.
    Biomed Pharmacother; 2018 Jan 20; 97():736-744. PubMed ID: 29102917
    [Abstract] [Full Text] [Related]

  • 12. Upregulated miR-132 in Lgr5+ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway.
    Zhang L, Guo X, Zhang D, Fan Y, Qin L, Dong S, Zhang L.
    Mol Carcinog; 2017 Sep 20; 56(9):2022-2034. PubMed ID: 28383763
    [Abstract] [Full Text] [Related]

  • 13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS.
    Cancer Res; 2007 Nov 15; 67(22):11012-20. PubMed ID: 18006847
    [Abstract] [Full Text] [Related]

  • 14. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
    Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y, Huang Q, Jiang L, Huang W, Cheng W, Liu Z.
    Mol Cell Biochem; 2010 Jul 15; 340(1-2):265-73. PubMed ID: 20224986
    [Abstract] [Full Text] [Related]

  • 15. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y.
    Drug Des Devel Ther; 2015 Jul 15; 9():5225-35. PubMed ID: 26396496
    [Abstract] [Full Text] [Related]

  • 16. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
    Sekino Y, Han X, Kawaguchi T, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Yasui W, Matsubara A.
    Int J Mol Sci; 2019 Aug 13; 20(16):. PubMed ID: 31412591
    [Abstract] [Full Text] [Related]

  • 17. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L.
    Mol Cancer; 2016 Nov 10; 15(1):70. PubMed ID: 27832783
    [Abstract] [Full Text] [Related]

  • 18. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI, Kim DK, Seo EJ, Choi EJ, Kwon YW, Jang IH, Lee JC, Kim HY, Shong M, Kim JH, Kim SJ.
    Thyroid; 2017 Nov 10; 27(11):1424-1432. PubMed ID: 28920531
    [Abstract] [Full Text] [Related]

  • 19. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
    Hao J, Madigan MC, Khatri A, Power CA, Hung TT, Beretov J, Chang L, Xiao W, Cozzi PJ, Graham PH, Kearsley JH, Li Y.
    PLoS One; 2012 Nov 10; 7(8):e40716. PubMed ID: 22870202
    [Abstract] [Full Text] [Related]

  • 20. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW, Wu X, Yin C, Chai S, Yao S, Kadioglu O, Efferth T, Ye Y, Lin G.
    J Ethnopharmacol; 2017 May 05; 203():110-119. PubMed ID: 28363522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.